Research programme: influenza A virus vaccines - AmVac

Drug Profile

Research programme: influenza A virus vaccines - AmVac

Alternative Names: AMV 411; Influenza A virus H5N1 vaccine - National Health Research Institutes/AmVac; Influenza A virus infections vaccine - AmVac; Prophylactic pandemic influenza vaccine - AmVac

Latest Information Update: 02 Dec 2014

Price : $50

At a glance

  • Originator AmVac
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza A virus infections

Most Recent Events

  • 02 Dec 2014 Preclinical development is ongoing in Switzerland
  • 20 Jun 2013 Preclinical trials of AMV 411 in Influenza-A virus infections (prevention) in Switzerland (Intranasal)
  • 01 Dec 2010 Early research in Influenza-A virus H5N1 subtype (prevention) in Switzerland (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top